SEARCH

SEARCH BY CITATION

References

  • 1
    Futreal PA, Coin L, Marshall M et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 17783.
  • 2
    Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 17580.
  • 3
    Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 94757.
  • 4
    Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 23808.
  • 5
    Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 1218.
  • 6
    Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 23946.
  • 7
    O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 9941004.
  • 8
    Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 80919.
  • 9
    Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 212939.
  • 10
    Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497500.
  • 11
    Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 891923.
  • 12
    D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v1169.
  • 13
    Clinical practice guideline for lung cancer. The Japan Lung Cancer Society, 2010. [Cited 9 Sep 2012.] Available from URL: http://www.haigan.gr.jp.
  • 14
    NCCN Clinical Practice Guidlines in Oncology, Non-Small Cell Lung Cancer. [Cited 9 Sep 2012.] Available from URL: 2010. http://www.nccn.org.
  • 15
    Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26: 98394.
  • 16
    Marchetti A, Normanno N, Pinto C et al. Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica 2010; 102: 11926.
  • 17
    Pirker R, Herth FJ, Kerr KM et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010; 5: 170613.
  • 18
    Inoue A, Kobayashi K, Usui K et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27: 1394400.
  • 19
    Tanaka T, Nagai Y, Miyazawa H et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007; 98: 24652.
  • 20
    Goto K, Satouchi M, Ishii G et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 2012; 23: 29149.
  • 21
    Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008; 14: 661824.
  • 22
    Malapelle U, de Rosa N, Bellevicine C et al. EGFR mutations detection on liquid-based cytology: is microscopy still necessary? J Clin Pathol 2012; 65: 5614.
  • 23
    Journal of Health and Welfare Statistics, Health and Welfare Statistics Association. Tokyo: Koseido, 2009 (in Japanese).
  • 24
    Ministry of Health, Labour and Welfare, Japan, 2011. [Cited 9 Sep 2012.] Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei10/dl/11_h7.pdf (in Japanese).
  • 25
    Nagai Y, Miyazawa H, Huqun H et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 727682.
  • 26
    Miyazawa H, Tanaka T, Nagai Y et al. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci 2008; 99: 595600.
  • 27
    Tanaka T, Matsuoka M, Sutani A et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010; 126: 6515.
  • 28
    Greer CE, Wheeler CM, Manos MM. Sample preparation and PCR amplification from paraffin-embedded tissues. PCR Methods Appl 1994; 3: S11322.
  • 29
    Liu D, Nakano J, Ueno M et al. A useful protocol for analyses of mutations of the epidermal growth factor receptor gene. Oncol Rep 2006; 15: 15035.
  • 30
    Sutani A, Nagai Y, Udagawa K et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006; 95: 14839.
  • 31
    Kimura H, Kasahara K, Kawaishi M et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006; 12: 391521.
  • 32
    Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007; 635: 10517.
  • 33
    Bai H, Mao L, Wang HS et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 26539.
  • 34
    Goto K, Ichinose Y, Ohe Y et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012; 7: 11521.
  • 35
    Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 36677.
  • 36
    Fujimoto H, Furumoto N, Takeda M et al. EGFR mutation test using the PNA-LNA PCR clamp performed in our company. Byori Gijutsu 2010; 73: 679.